17 Analysts Assess Biogen: What You Need To Know
17 Analysts Assess Biogen: What You Need To Know
17位分析師評估渤健公司：您需要了解的信息
The perception of Biogen by financial experts is analyzed...Analysts' ratings for Biogen (NASDAQ:BIIB) over the last quarter vary from bullish to bearish, as provided by 17 analysts.
在過去一個季度，17位分析師對渤健公司（納斯達克：BIIB）的分析師評級從看好到看淡不等。
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
下表總結了他們近期的評級，揭示了過去30天內情緒的變化，並與之前幾個月進行了比較。
In the assessment of 12-month price targets, analysts unveil insights for Biogen, presenting an average target of $224.76, a high estimate of $300.00, and a low estimate of $138.00. A 15.18% drop is evident in the current average compared to the previous average price target of $265.00.
在對12個月價格目標的評估中，分析師揭示了對渤健公司的見解，提出了平均目標價爲224.76美元，最高估計爲300.00美元，最低估計爲138.00美元。與之前265.00美元的平均價格目標相比，目前的平均價格顯示出15.18%的下降。
Analyzing Analyst Ratings: A Detailed Breakdown
分析分析師評級：詳細剖析
The perception of Biogen by financial experts is analyzed...
金融專家對渤健公司...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間